A phase II trial of temsirolimus in second-line metastatic urothelial cancer

Medical Oncology

Volumn 29, Issue 4, 2012, Pages 2870-2876

  Gerullis, H ^a,b,c   Eimer, C ^a   Ecke, T H ^d   Georgas, E ^a   Freitas, C ^a   Kastenholz, S ^c   Arndt, C ^c   Heusch, C ^a,c   Otto, T ^a,b,c  

^a Lukaskrankenhaus GmbH   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

^c German Centre for Assessment and Evaluation of Innovative Techniques in Medicine DZITM   (Germany)

^d HELIOS Klinikum Bad Saarow   (Germany)

Author keywords

Clinical trial; Metastatic disease; mTOR inhibition; Phase II study; Second line; Temsirolimus; Urothelial carcinoma

Indexed keywords

CARBOPLATIN; CISPLATIN; DIMETINDENE; GEMCITABINE; HISTAMINE H1 RECEPTOR ANTAGONIST; PACLITAXEL; PLATINUM; TEMSIROLIMUS;

ABLATION THERAPY; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CYSTECTOMY; DISEASE COURSE; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; MALE; METASTASIS; METASTATIC TRANSITIONAL CARCINOMA; NEPHROURETERECTOMY; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RATING SCALE; THROMBOCYTOPENIA; TRANSITIONAL CELL CARCINOMA; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, TRANSITIONAL CELL; FEMALE; HUMANS; MALE; MIDDLE AGED; PROTEIN KINASE INHIBITORS; QUALITY OF LIFE; SIROLIMUS; URINARY BLADDER NEOPLASMS;

EID: 84868000731     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0216-x     Document Type: Article

References (27)

1. Bellmunt J, Albiol S. Chemotherapy for metastatic or unresectable bladder cancer. Semin Oncol. 2007;34:135-44.
2. Bellmunt J, Theodore C, Demkov T, Komyakov B, Sengelov L, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol. 2009;27:4454-61.
3. Albers P, Park SI, Niegisch G, Fechner G, Steiner U, et al. Randomized phase III trial of 2nd line gemcitabine and paclitaxel chemotherapy in patients with advanced bladder cancer: short-term versus prolonged treatment [German Association of Urological Oncology (AUO) trial AB 20/99]. Ann Oncol. 2011;22:288-94.
4. Wu X, Obata T, Khan Q, Highshaw RA, De Vere White R, et al. The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. BJU Int. 2004;93:143-50.
5. Mansure JJ, Nassim R, Chevalier S, Rocha J, Scarlata E, et al. Inhibition of mammalian target of rapamycin as a therapeutic strategy in the management of bladder cancer. Cancer Biol Ther. 2009;8:2339-47.
6. Schedel F, Pries R, Thode B, Wollmann B, Wulff S, et al. mTOR inhibitors show promising in vitro activity in bladder cancer and head and neck squamous cell carcinoma. Oncol Rep. 2011;25:763-8.
7. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, et al. The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365-76.
8. Torisel [package insert]. Philadelphia PWPI.
9. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228-47.
10. Gehan EA. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis. 1961;13:346-53.
11. EL Kaplan MP. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-81.
12. Galanis E, Buckner JC, Maurer MJ, Kreisberg JI, Ballman K, et al. Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North central cancer treatment group study. J Clin Oncol. 2005;23:5294-304.
13. Margolin K, Longmate J, Baratta T, Synold T, Christensen S, et al. CCI-779 in metastatic melanoma: a phase II trial of the California cancer consortium. Cancer. 2005;104:1045-8.
14. Javle MM, Shroff RT, Xiong H, Varadhachary GA, Fogelman D, et al. Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies. BMC Cancer. 2010;10:368.
15. Pandya KJ, Dahlberg S, Hidalgo M, Cohen RB, Lee MW, et al. A randomized, phase II trial of two dose levels of temsirolimus (CCI-779) in patients with extensive-stage small-cell lung cancer who have responding or stable disease after induction chemotherapy: a trial of the eastern cooperative oncology group (E1500). J Thorac Oncol. 2007;2:1036-41.
16. Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, et al. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs. 2005;23:357-61.
17. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol. 2004;22:909-18.
18. Bachner M, De Santis M. Second-line therapy in bladder cancer. Curr Opin Urol. 2009;19:533-9.
19. Logothetis CJ, Dexeus FH, Finn L, Sella A, Amato RJ, et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J Clin Oncol. 1990;8:1050-5.
20. Igawa M, Ohkuchi T, Ueki T, Ueda M, Okada K, et al. Usefulness and limitations of methotrexate, vinblastine, doxorubicin and cisplatin for the treatment of advanced urothelial cancer. J Urol. 1990;144:662-5.
21. Gerullis H, Ecke TH, Janusch B, Arndt C, Heidari M, et al. Long-term response in advanced bladder cancer involving the use of temsirolimus and vinflunine after platin resistance. Anticancer Drugs. 2011;22:940-3.
22. Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17:3173-81.
23. Bellmunt J, Choueiri TK, Fougeray R, Schutz FA, Salhi Y, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol. 2010;28:1850-5.
24. Choueiri TK, Ross RW, Jacobus S, Vaishampayan U, Yu EY et al. Double-blind, randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated metastatic urothelial cancer. J Clin Oncol. 2012;30(5):507-12.
25. Milowsky MI, Regazzi AM, Garcia-Grossman IR et al. Final results of a phase II study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the urothelium. J Clin Oncol. 2011;29(suppl; abstr 4606).
26. Seront E, Rottey S, Sautois B et al. A single arm, multicenter, phase II trial of everolimus as monotherapy in the palliative treatment of patients with locally advanced or metastatic transitional cell carcinoma after failure of platinum-based chemotherapy. J Clin Oncol. 2010;28(No 15-suppl; abstr e15087).
27. www.clinicaltrials.gov/ct2/show/NCT00933374.